Adding raltegravir to optimized background treatment in patients with virological failure has proved to be effective in clinical trials in reducing viral load to undetectable levels in the majority of patients, even in the presence of triple-class drug-resistance (PI, NRTI, NNRTI). However, it is not known whether similar results can be expected in a context of common clinical practice, and what may be the rate of success in the presence of newer drugs who recently became available.
Virological response to treatment in patient who start raltegravir in combination with newer agents in current clinical practice
S. Baroncelli;V. Tozzi;C. Tommasi;D. Segala;A. Vivarelli;G. Verucchi;G. Guaraldi;G. Nardini;M. Di Gregorio;S. Lucattini;
2011
Abstract
Adding raltegravir to optimized background treatment in patients with virological failure has proved to be effective in clinical trials in reducing viral load to undetectable levels in the majority of patients, even in the presence of triple-class drug-resistance (PI, NRTI, NNRTI). However, it is not known whether similar results can be expected in a context of common clinical practice, and what may be the rate of success in the presence of newer drugs who recently became available.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
